Terms ending in 2042
Every in-force patent on Purdue Pharma L.P.'s record whose computed term ends in 2042, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,653,808 | Compounds for Treating Multiple Myeloma In force · High confidence | Knoa Pharma LLC | In force | High confidence | |
| US 12,371,427 | Polymorphic Forms of a Substituted-Quinoxaline-Type Bridged-Piperidine Compound In force · High confidence | Knoa Pharma LLC | In force | High confidence | |
| US 12,377,076 | Compounds for Treating Lymphoma or a T-Cell Malignant Disease In force · High confidence | Knoa Pharma LLC | In force | High confidence |
3 of 3 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by Purdue Pharma L.P..
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.